Synapse - Shanu Modi

Results (19)

Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: A randomized trial

Journal Article

Scott, J. M.; Lee, J.; Herndon, J. E.; Michalski, M. G.; Lee, C. P.; O'Brien, K. A.; Sasso, J. P.; Yu, A. F.; Rowed, K. A.; Bromberg, J. F.; more...
European Heart Journal (2023)

Fulltext@MSK | Save

Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study

Journal Article

Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients

Meeting Abstract

Barrios, D. M.; Wang, D. G.; Blinder, V. S.; Bromberg, J.; Drullinsky, P.; Funt, S. A.; Jhaveri, K. L.; Lake, D.; Lyons, T.; Modi, S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

Journal Article

Wang, D. G.; Barrios, D. M.; Blinder, V. S.; Bromberg, J. F.; Drullinsky, P. R.; Funt, S. A.; Jhaveri, K. L.; Lake, D. E.; Lyons, T.; Modi, S.; more...
Breast Cancer Research and Treatment (2020)

Fulltext@MSK | Save

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)

Meeting Abstract

Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Phase II study of paclitaxel and dasatinib in metastatic breast cancer

Journal Article

Morris, P. G.; Rota, S.; Cadoo, K.; Zamora, S.; Patil, S.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; more...
Clinical Breast Cancer (2018)

Fulltext@MSK | Save

Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Meeting Abstract

Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
Cancer Research (2015)

Fulltext@MSK | Save

Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)

Meeting Abstract

Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Meeting Abstract

Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
Cancer Research (2015)

Fulltext@MSK | Save

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Journal Article

Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save